Status:
UNKNOWN
The Montreal Cognitive Assessment.Test in Adults With Sickle Cell Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Sickle Cell Anemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study will assess the performances of the Montreal Cognitive Assessment (MoCA) to screen for cognitive impairment in adults with sickle cell anemia. The results of the MoCA and its subscores will...
Detailed Description
Sickle cell anemia is a monogenic disease affecting the beta-chain of hemoglobin. Cognitive impairment is more prevalent in patients with sickle cell disease than in matched unaffected individuals. Va...
Eligibility Criteria
Inclusion
- Sickle cell disease, SS or SBêta0 subtypes only
- Attending a consultation or a daycare hospitalization in the Tenon hospital sickle cell center
- Aged 18 years old or more
- Providing written informed consent
- With Health Insurance
Exclusion
- Obvious cognitive impairment of neurologic (e.g. previous stroke) or psychiatric origin (e.g. psychotic disorder with negative symptoms)
- Insufficient French language fluency to understand the tests, inability to read and write or with no schooling beyond primary school
- Anticipated unavailability in the next 6 months
- Patients under supervision \& guardianship
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT05347043
Start Date
May 1 2022
End Date
June 1 2023
Last Update
May 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Internal Medicine Department - Tenon
Paris, France, 75020